Home / Health / Abivax Drug Shows Promise in Chronic Inflammatory Bowel Disease Study
Abivax Drug Shows Promise in Chronic Inflammatory Bowel Disease Study
2 Jun
Summary
- Abivax's experimental drug obefazimod showed positive results in a late-stage trial.
- The drug is being studied for chronic inflammatory bowel disease.
- Positive trial outcomes could lead to takeover interest in Abivax.
Abivax SA has announced a significant development regarding its experimental drug, obefazimod. The drug has successfully met its primary objective in a crucial late-stage clinical trial focused on treating chronic inflammatory bowel disease.
These positive trial outcomes represent a major milestone for Abivax and could potentially pave the way for future acquisition offers for the French biotechnology firm. The success of obefazimod in this pivotal study suggests a promising new avenue for patients suffering from this chronic condition.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
